ClinicalTrials.gg
TerminatedNCT02491970RECONFFIRMUpdated May 16, 2018

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

A Phase 4 interventional study of Fluticasone/Formoterol and Fluticasone/Salmeterol in Asthma, sponsored by Mundipharma Korea Ltd. Terminated. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.

Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Treatment

Why this study was terminated
Difficulty of patients enrollments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
131st of 146
15 · median 100
Started
2015
with 6 others
Phase 4
52 of 147
1 open now
Registered
115th of 147
by date

Among the 147 studies testing fluticasone in Asthma, this one is the 131st largest by enrollment of the 146 interventional ones that give a count, is one of 7 that started in 2015, is one of 52 in phase 4, and was the 115th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate superiority of Fluticasone/Formoterol (Flutiform®) to Fluticasone/salmeterol based on the small airway function by assessing the Impulse Oscillometic System (IOS) in uncontrolled asthma patients requiring ICS/LABA concomitant treatment.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (over 19 years) asthma patients
  2. Patients who have a history of mild-to-moderate-severe, persistent asthma for at least 6 months prior to Screening.
  3. Patients who were required to demonstrate a of ≥ 40 % and ≤ 85% of predicted normal values during screening period following appropriate withholding of asthma medications (if applicable).
  4. Patients who were required to show reversibility of ≥15% FEV1 after salbutamol inhalation (2 actuations, 100µg per actuation) from the pre- salbutamol value at screening
  5. Patients who have uncontrolled asthma by Seretide® 250/50 defined as ACT less than 20
  6. Patients who showed R5-20 more than 0.1 kPa/L/s
  7. Blood eosinophil count > 300/µL on screening visit
  8. Female patients of must have a negative urine pregnancy test at Screening.
  9. Patients who are able to use the inhaler
  10. Patients who is willing to voluntarily sign the study consent form

Exclusion criteria

Exclusion Criteria:

  1. Patients who have experienced life-threatening asthma within 12 months prior to screening or respiratory infection within 4 weeks prior to screening, or patients who have experienced any emergency visit or hospitalization due to acute asthma symptoms within 4 weeks prior to screening
  2. Patients who have diagnosed as disease or non- reversible pulmonary disease or patients who currently have active pulmonary disease (eg. , cystic fibrosis, bronchiectasis, active tuberculosis)
  3. Patients who have diagnosed as laryngitis, chronic sinusitis, infectious rhinitis or allergic rhinitis within 4 weeks prior to screening, or patients who have had any symptoms of acute exacerbation or purulent discharge by the disease above within 2 weeks prior to screening
  4. Current smoker or past smoker defined as below:

    • Current smoker: smoking history within 12 months prior to screening
    • Past smoker: smoking amount ≥10 pack year*

      • Pack year (PY) calculation: average amount of smoking per day (pack) x duration of smoking (year)
  5. Patients who currently are pregnant or lactating
  6. Patient who had taken systemic within 4 weeks prior to screening
  7. Patients who had taken omalizumab within 24 weeks prior to screening
  8. Patients who had taken the following medications within 1 week prior to screening:

    • potent inhibitors
    • β-blockers
    • monoamine oxidase inhibitor
    • TCA (tricyclic antidepressants)
    • quinidine-type anti arrhythmic
    • Leukotriene anatagonist
    • Astemizole
  9. Patients who are participating or going to participate in any interventional clinical trials
  10. prolongation in result at screening
  11. Patients with hypersensitive to products or to any component of the drug
  12. Patients who are judged difficult to participate in this investigation by the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Fluticasone/Formoterol

    Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation

    Drug: Fluticasone/Formoterol

  • Active comparator
    Fluticasone/Salmeterol

    Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation

    Drug: Fluticasone/Salmeterol

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy superiority as measured by Impulse Oscillometric System

    To compare Fluticasone/Formoterol to Fluticasone/salmeterol, assessing the change in the mean R5-R20 measured by the Impulse Oscillometic System (IOS) in uncontrolled asthma patients

    Time frame: 12 weeks

Secondary outcomes

  1. Incidence of adverse drug reactions as a measure of safety

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Apr 2017, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2015
First posted
Jul 8, 2015
StartActual
Aug 31, 2015
Primary completionActual
Apr 6, 2017
CompletionActual
May 2017
Last update
May 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02491970
Responsible party
Sponsor
First posted
Jul 8, 2015
Start date
Aug 31, 2015
Primary completion
Apr 6, 2017
Completion
May 2017
Last update
May 16, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Formoterol

Start the discussion